CASI Pharmaceuticals
CASI
CASI was delisted on the 25th of February, 2026.
23 hedge funds and large institutions have $5.93M invested in CASI Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 2 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
5% more funds holding
Funds holding: 22 → 23 (+1)
0.64% more ownership
Funds ownership: 19.84% → 20.48% (+0.64%)
21% less capital invested
Capital invested by funds: $7.52M → $5.93M (-$1.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$158K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$51.7K |
| 3 |
WSCM
Wellington Shields Capital Management
New York
|
+$12.4K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$6.85K |
| 5 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$2.69K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$20.1K |
| 2 |
Renaissance Technologies
New York
|
-$1.22K |
| 3 |
TCOV
Trust Company of Vermont
Brattleboro,
Vermont
|
-$28 |
| 4 |
WWA
Wingate Wealth Advisors
Lexington,
Massachusetts
|
-$6 |
CASI Hedge Fund Activity: Q1 2025 in Review
23 of the 7,471 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q1 2025, worth a combined $5.93M — down 21% from $7.52M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new CASI positions and 2 closed out — a net gain of 1 holder — while 5 added to existing stakes and 2 trimmed.
The largest buyer was Woodline Partners, adding an estimated $158K. The largest seller was UBS Group, cutting an estimated $20.1K.
- 23 institutional investors held CASI Pharmaceuticals (CASI) as of Q1 2025, up from 22 in Q4 2024.
- Funds reported $5.93M of CASI Pharmaceuticals stock for Q1 2025, down 21% quarter-over-quarter.
- 3 funds opened new CASI Pharmaceuticals positions in Q1 2025 and 2 closed out, a net change of +1 holder.
- The largest CASI Pharmaceuticals buyer in Q1 2025 was Woodline Partners, an estimated $158K added.
- The largest CASI Pharmaceuticals seller in Q1 2025 was UBS Group, an estimated $20.1K sold.
Based on aggregated 13F filings for Q1 2025.